Daratumumab (Dara) is a humanized IgG1 (ĸ subclass) monoclonal antibody targeting the CD38 epitope, which has been approved by the USA Food and Drug Administration for the treatment of patients with relapsed and newly diagnosed multiple myeloma. The gene discussed is CD38; the disease is plasma cell myeloma.